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In vivo platelet activation with in vitro hyperaggregability to arachidon-
ic acid in renal allograft recipients. Renal allograft recipients were
investigated to determine the extent and possible nature of in vivo
platelet activation. In 92 allografted patients stable for more than 4
months' duration, intraplatelet serotonin in circulating platelets was
depleted significantly. In a further 16 patients studied serially for 12 to
16 weeks following transplantation, intraplatelet serotonin fell abruptly
within 4 days from transplantation to very low levels, and remained
thus for 10 weeks, rising toward normal at about 12 weeks. Although
some patients showed abrupt falls in intraplatelet serotonin coincident
with acute rejection episodes, there was no difference in intraplatelet
serotonin in seven patients whose grafts functioned well immediately
and remained stable, and seven in whom repeated rejection led to graft
loss within 3 months. Thus, these tests of platelet function do not permit
diagnosis of rejection or prediction of graft outcome. Plasma platelet
factor 4 (PF4) concentrations, in contrast, were normal in most patients
during the first 6 weeks after grafting, then rose and remained abnormal
up to 13 years following the allograft in the long-term stable graft
recipients. This discrepancy suggests a different mode of platelet
activation in the first few weeks after grafting from subsequent months.
Despite universal depletion of intraplatelet amines and a-granule con-
tents only four out of 14 early allograft recipients had an abnormal
bleeding time, and platelet aggregation thresholds with adenosine-5'-
diphosphate and collagen were not different from controls. However,
thresholds for platelet aggregation with arachidonic acid were reduced
significantly (P < 0. 01) and thromboxane B2 generation was increased
in vitro. There was no correlation between depletion of intraplatelet
serotonin and circulating platelet-agglutinating material, but nine of 17
biopsy specimens from rejecting allografts taken during the first 3
months showed extensive glomerular localization of platelet membrane
antigens and PF4.
Activation plaquettaire in vivo avec hyperagregabilité in vitro a l'acide
arachidonique chez des receveurs d'allogreffe rénale. Des receveurs
d'allogreffe rénale ont éte étudiés afin de determiner le degre et la
nature possible de l'activation plaquettaire in vivo. Chez 92 malades
greffés stables de plus de 4 mois, la sérotonine intra plaquettaire des
plaquettes circulantes était significativement diminuée. Chez 16 autres
malades étudiés de facon sériée au cours des 12 a 16 semaines après la
transplantation, la sérotonine intra plaquettaire a chute brutalement
dans les 4 jours apres la transplantation a des niveaux très bas, elle est
restée inchangee pendant 10 semaines, puis est revenue vers la normale
a 12 semaines environ. Bien que certains malades aient présenté des
chutes brutales de la sérotonine intra plaquettaire coincidant avec des
episodes de rejet aigu, il n'y avait pas de difference dans Ia sérotonine
intra plaquettaire entre sept malades dont le greffon fonctionnait bien
d'emblée et restait stable, et sept chez qui des rejects répétés ont
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conduit a la perte du greffon en 3 mois. Ainsi, ces tests de fonctionne-
ment plaquettaire ne permettent pas le diagnostic de rejet ou Ia
prediction du devenir du greffon. Les concentrations plasmatiques du
facteur plaquettaire 4 (PF 4), au contraire, étaient normales chez la
plupart des malades au cours des 6 premieres semaines apes la greffe,
puis s'élevaient et restaient anormales jusqu'à 13 ans après la greffe
chez des malades avec un greffon stable a long terme. Cette discordance
suggere un modèle different de l'activation plaquettaire entre les toutes
premieres semaines après Ia greffe et les mois suivants. Malgré une
déplétion génerale en amines et contenus des a-granules intra-plaquet-
taires, seulement quatre des 14 receveurs d'allogreffe récents avaient un
temps de saignement anormal, et leurs seuils d'agrégation plaquettaire
avec l'adenosine-5'-diphosphate et le collagene ne différaient pas des
contrôles. Cependant, les seuils d'agrégation plaquettaire avec l'acide
arachidonique étaient significativement réduits (P < 0,01) et Ia généra-
tion de thromboxane B2 était augmentée in vitro. Ii n'y avait pas de
correlation entre la déplétion en sérotonine intraplaquettaire et le
materiel circulant agglutinant les plaquettes, mais 9 de 17 specimen
biopsies de greffons en rejet faites pendant les 3 premiers mois
montraient une localisation glomerulaire extensive des antigènes mem-
branaires plaquettaire et du PF 4.
There is evidence that platelets are involved in host reactions
directed against allografted kidneys. One of the early observa-
tions in the destruction of allografts in dogs, primates, and
humans was of platelet aggregates within glomerular capillaries
[1—3]. The more acute the rejection, the more profound the
platelet involvement, particularly in recipients with circulating
antibodies [3—7] and in xenograft destruction [8, 9]. This platelet
sequestration in the grafted kidney may be clinically evident as
thrombocytopenia [10—121. Renal uptake of platelets and their
release back into the circulation after treatment of rejection was
demonstrated using platelets labelled with 51Cr [13] and more
recently, "In oxine [14—15]. In dogs bearing stable renal
allografts, platelet turnovers are accelerated for 6 months
following transplantation [161.
The measurement of platelet turnover is expensive and time-
consuming to perform, renal biopsies can only be performed at
intervals and are subject to sampling error, and there are many
causes besides rejection for thrombocytopenia in immunosup-
pressed allograft recipients. Recently, measurements of sub-
stances both within platelets and in the plasma have been
demonstrated to be useful indices of in vivo platelet activation.
These substances include intraplatelet amines, such as seroto-
nm [17] or adenosine-5'-diphosphate (ADP) [181, and platelet-
specific proteins such as platelet factor 4 (PF4) [191 and /3-
thromboglobulin (J3-TG) [20]. We have shown previously that
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intraplatelet serotonin is generally depleted [21] and plasma
concentrations of PF4 and p-TG are increased [22] in patients
with glomerular disease.
Therefore, we examined concentrations of serotonin in circu-
lating platelets in recipients of renal allografts and compared
these values with plasma concentrations of PF4. We also
undertook an examination of the functional capacity of periph-
eral blood platelets after transplantation, since it might be
expected that amine and a-granule (PF4, TG)-depleted plate-
lets might show abnormal properties if they returned to the
circulation. We measured thresholds for irreversible aggrega-
tion using ADP, arachidonic acid, and collagen in vitro. Finally,
to examine some possible modes of platelet activation, we
examined the presence of platelet-derived material within re-
jecting kidneys by antibodies directed against platelet mem-
brane antigens and PF4, using an indirect immunofluorescent
technique, and measured the titer of platelet-agglutinating mate-
rials in the serum.
Methods
Control subjects and patients. Thirty-eight control subjects
were recruited from among laboratory staff and visitors. The
ages (19 to 48 years) were similar to those of the transplant
subjects. Intraplatelet serotonin and PF4 concentrations were
measured in all, and platelet aggregation threshold with arachi-
donic acid in 34, with ADP and collagen in 17.
Transplant recipients. Altogether 113 transplanted patients
were studied. In 97 patients stable allografts had been present
from 6 months up to 13 years, and the patients were taking a
stable immunosuppressive regime of 0.21 mgIkgI24 hr predni-
sone and 2 mg/kg/24 hr azathioprine; none were taking any
specific antiplatelet drugs, although 32 were taking propanolol
in doses of 80 to 360 mg!24 hr for hypertension, 8 hydrallazine,
and 46 furosemide (100 to 200 mg daily). None were taking
other drugs which might affect platelet function, for example,
tranquillizers or diazepam. Their serum albumin ranged from 37
to 51 g!liter and hematocrit from 38 to 50%. Each patient was
studied on a single occasion.
In another 16 allograft recipients (2 live donor and 14 cadaver
donor) transplanted between December 1979 and March 1980,
serial samples were taken for measurement of intraplatelet
serotonin, plasma PF4 concentrations, serum platelet aggluti-
nating titre and platelet aggregation thresholds for 12 to 16
weeks, three times a week. These patients all took the same
constant dose of azathioprine (2 mg/kg/24 hr), except when
leukopenia or thrombocytopenia developed, but tapering doses
of prednisone were administered according to a "high" or
"low" dose protocol as part of a trial of different corticosteroid
regimes. The "high" dose regime was 1.7 mg!kg!24 hr to 0.28
mg!kg!24 hr at the end of 12 weeks, the "low" dose regime from
0.60 mg!kg!24 hr to 0.28 mg!kg!24 hr over the same period.
When acute rejections were diagnosed (mean 3.3 episodes!
patient in the 3-month period of study), they were treated by a
standard course of three intravenous injections of methyl
prednisolone 1 g on consecutive days, without alteration in the
baseline immunosuppression.
Threshold concentrations for platelet aggregation using ADP,
arachidonic acid, and collagen were measured on 57 occasions
in 37 recipients, plasma PF4 concentrations in 73 recipients on
73 occasions, and titers of platelet-agglutination on 42 patients.
Intraplatelet serotonin was measured on 396 samples during the
first 3 months.
Dialysis patients. Twenty-three patients awaiting transplan-
tation on regular hemodialysis were studied to assess the
starting point for intraplatelet serotonin. Each was dialyzed
three times per week on a dialyzer (Gambro Lundia®). Samples
were taken just before dialysis.
Transplant biopsy specimens were taken under local analge-
sia with the patient supine using a Becton-Dickinson biopsy
needle with fluoroscopic control from 17 allografts within 12
weeks of grafting. The biopsy cores were processed for optical
and electron microscopy, but also snap-frozen in liquid nitrogen
into TissueTek® OTC compound on a chuck, and later sec-
tioned on a cryostat at approximately 5 m.
Platelet counts were performed using a Coulter counter
model ZB 1 on citrated plasma. Platelet size was analyzed using
a C-bOO Channelyser® with a 70-is aperture tube and a graphi-
cal recording system. The percentage of platelets of volume
< 3.0, 3 to 4, 3.8 to 8.0, and >8 tm3 was determined by
planimetry.
Intraplatelet serotonin concentration was determined by the
spectrofluorimetric method of Drummond and Gordon as previ-
ously described [17] and expressed as ng!b09 platelets.
Platelet factor 4 (PF4) was measured in blood taken through a
l9-g siliconized needle and plastic syringe into plastic tubes
containing cold theophylline-EDTA maintained at 4°C through-
out. Platelet-poor plasma was separated by immediate centnfu-
gation at x 2000g for 20 mm at 4°C. The plasma was kept frozen
at —70°C, and the PF4 concentration was measured by radio-
immunoassay [23] using the kit supplied by Abbott Labora-
tories, North Chicago, Illinois. Results were expressed in ng!ml
platelet-poor plasma.
Bleeding times were determined by using a Becton Dickinson
Simplate Il® device for obtaining a standard incision.
Platelet aggregation was performed on platelet-rich plasma
(PRP) prepared from citrated blood (9:1) by centrifugation at
xl36g, using ADP (Sigma Chemical Co., St. Louis, Missouri),
collagen (Medikent International Ltd), and arachidonic acid
(Sigma, 99% pure). The platelet counts in the PRP varied from
110 to 410 x l0 liter. In each case, the minimum threshold
concentration required to produce aggregation within 3 mm
which did not reverse spontaneously was determined as de-
scribed previously [24] using a dual-channel aggregometer
(Payton Instruments) [25]. At least four and usually six concen-
trations of each agent were added to each PRP sample.
The serum titer of high molecular weight platelet agglutinat-
ing material (PAM) was determined by the platelet agglutination
test, performed on a microtiter plate essentially after the
method by Penttinen and Myllyla, as previously described [26].
Production of thromboxane B2 (Tx B2) by unstirred platelet-
rich plasma in vitro was measured in 1.0 mmoles/liter arachi-
donic acid (Sigma, 99% pure), incubated for 5 mm at 37°C. At
the end of incubation, 100 tl of PRP was diluted with 400 i1
cold phosphate-buffered saline and frozen in liquid nitrogen.
The Tx B2 concentration in the supernatant was measured by
radioimmunoassay. The antibody was kindly donated by Dr. J.
Bryan Smith (Cardeza Foundation for Hematologic Research,
Philadelphia, Pennsylvania). Results were expressed as ng
TX B2/3 X 108 platelets/S mm incubation.
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Fig. 1. Inrraplatelet serotonin concentration (ng/109 platelets) following
renal transplantation. Data up to 90 days was derived from 396
observations in 16 patients studied serially, that from 120 days to 2
years from single observations in each of 97 stable allografted recipi-
ents. Means SEM are shown for each 10 days of study (40 to 48
observations at each point), and then for each of 4 out of 12—1 year, 1
to 2 years, and more than 2 years, The dotted lines show the 95%
confidence limits for intraplatelet serotonin in normal individuals. Data
from patients awaiting transplantation while on regular dialysis are
shown on the left.
Anti-platelet membrane antibody. Preparation of this anti-
body has been described in detail elsewhere [27]. In brief,
disrupted and washed platelet membranes were used to immu-
nize rabbits, and the serum absorbed with red cells and clotted
fibrin until the only reactivity was with platelets; no reaction
was noted with tissue, or buffy coat cells. Immunoelectronmi-
croscopy demonstrated that the antiserum localized only to the
platelet membrane. The presence of this antibody fixed to the
washed cryostat sections of the allografted kidneys was demon-
strated by a fluorescein-conjugated swine anti-rabbit IgG anti-
serum, with appropriate controls. The anti-PF4 antiserum used
in the immunofluorescent study was the kind gift of Dr. D. S.
Pepper (Edinburgh, Scotland). The presence of anti-PF4 anti-
body was demonstrated by indirect immunofluorescence as for
platelet membrane antigens.
Statistics. Student's t test, x2 test, and the Wilcoxon rank
sum tests were used where appropriate.
Results
The platelet count of the 38 controls was 329 76 (mean
SD), range 170 to 470 x 109/Iiter, and that of 97 stable transplant
recipients was 270 120, range 30 to 610 x 109/liter. Thirteen
transplant patients had platelet counts of less than 170 x l0/
liter. Modal platelet volume and proportion of small, medium,
and large platelets were indistinguishable from normal subjects,
except in the two patients who developed severe thrombocyto-
penia during the study, in whom there was a precipitate fall in
larger platelets.
Intraplatelet serotonin concentration (Fig. 1). The 95% confi-
dence limits for the control subjects were 300 to 980 ng/109
platelets, the geometric mean being 473 ngIlO9 platelets. The
dialysis patients' intraplatelet serotonin was reduced signifi-
cantly, but the mean was just at the lower limit of normal.
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Fig. 2.Serial plasma creatinine (A) and serial intraplatelet serotonin (B)
in 14 allograft recipients judged to have "good" function and 'poor"
function during the serial study for 12 to 16 weeks following the
transplant. All but one of the "poor" grafts eventually failed (five
during the study) and one patient died (cross). Despite the large clinical
difference in graft performance, there was no difference in intraplatelet
serotonin, all being very low during the period of study.
Intraplatelet serotonin fell to very low levels within a week of
transplantation, reaching a nadir at 20 to 40 days post trans-
plant. Thereafter the concentrations slowly rose, rising at 12
weeks to approach the lower limit of normal. The data from the
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Fig. 3. Behavior of intraplatelet serotonin concentrations during 11
episodes of reversible rena/failure diagnosed clinically as rejection, in
which the initial level of intraplatelet serotonin was normal or near
normal. In nine (•) there was an abrupt fall in intraplatelet serotonin
concentration, while in two (A—A) intraplatelet serotonin remained low
normal.
97 recipients with stable allografts (Fig. 1, right) is presented for
those with <1 y, ito 2 y, and >2 y, and the concentrations are
the same as those reached in the serial study at 3 months after
grafting, with a mean just below the fifth percentile for normal
subjects.
Figure 2 compares the plasma creatinine concentrations (A)
and intraplatelet serotonin concentrations (B) in seven grafts
judged to have "good" allograft function, and seven grafts
judged to have "poor" ailograft function during the serial study
of 16 allografts (two patients were excluded from this analysis
because their pattern of behavior did not fit either category; one
had a rapid onset of function but stabilized at a plasma
creatinine of 200 moles/liter, and the other had an irregular
pattern of plasma creatinine rising eventually to 400 smoles/
liter). Despite the difference in ultimate graft function, there
was no difference between the intraplatelet serotonin concen-
trations in the two groups of patients except at 80 days, when
the "poor" functioning grafts showed a significantly higher
(more normal) intraplatelet serotonin. In those with "poor"
function there was no correlation between intraplatelet seroto-
nm and the plasma creatinine (data not shown). The number of
treated acute rejection episodes was not different in the two
groups (2.9 vs. 3.4). There was no difference between those
patients taking propanolol (84 62 SD) and not taking propano-
lol (95 80 SD), or those on initial "high" or "low" dose
prednisone regime.
The generally low levels of intraplatelet serotonin during the
first 3 months — often zero — precluded detailed examination
of whether the intraplatelet serotonin fell acutely during acute
rejections. However, in 11 acute rejection episodes occurring at
a time when intraplatelet serotonin was near or within normal
limits the level fell precipitously in nine (Fig. 3).
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Fig. 4. Plasma PF4 measurements in renal allograft recipients follow-
ing transplantation. Data on the left are from patients studied serially,
data on the right (> 90) from stable allografts in place from 90 days to 13
years. Up to 50 days following transplantation, only 9 out of 20 points
are abnormal; the majority are only slightly raised (< 20 ng/ml). In
contrast, all but 9 of 30 values in the long-term stable allografts were
abnormal (P < 0.001, x2 test). The dotted line shows the upper limit of
values from normal subjects (< 8 ng/ml).
Three patients were given dipyridamole, 10 mgIkgI24 hr for 4
weeks, starting at week 6 after transplantation. No effect was
seen on the intraplatelet serotonin concentrations; two episodes
of acute rejection with a fall in intraplatelet serotonin were
observed while taking the drug.
Plasma PF4 concentration (Fig. 4). The PF4 concentrations
were initially normal (<8 ng!ml) in the majority of observations,
in contrast to the intraplatelet serotonin, but by 3 months the
PF4 levels in the majority of patients rose. In the stable long-
term allografted patients most observations were abnormal and
remained so up to 13 years following transplantation.
Bleeding time. Bleeding times were 223 66 sec in controls
(mean SD) and 305 ill sec in 14 transplant recipients
studied serially (P = 0.01). Two thrombocytopenic patients
with bleeding times of >1000 sec were excluded from this
analysis; one had a platelet count of only 30 x 109/liter because
of azathioprine toxicity, and another of 50 x l09/liter in
association with cytomegalovirus infection. The bleeding times
were significantly correlated to platelet count in the transplant
recipients (P <0.05) but were not related significantly to the
intraplatelet serotonin concentration (data not shown).
Platelet threshold aggregation study (Fig. 5). The threshold
for ADP was indistinguishable between controls and allografted
recipients, while that for collagen showed an excess of patients
with subnormal aggregability (high thresholds); this difference,
however, did not reach 1:20 significance using the Wilcoxon
rank sum test. The most striking observation was a highly
significant decrease in threshold for irreversible aggregation
with arachidonic acid, indicating platelet hyperaggregability (P
<0.01, Wilcoxon rank sum test). This hyperaggregability per-
sisted throughout the 12-week period of the serial study and was
also present in 17 patients with chronic stable allografts of more
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than 4 months' duration. The plasma albumin concentrations
were normal in all patients studied (range, 34 to 49 g/liter).
Thromboxane B2 (TX B2) production by platelets in vitro. The
TxB2 production by platelets from normal controls was 96 to
426 ng/3 X 1O platelets/S' incubation (mean 2 SD) in 1.0
mmoles/liter arachidonic acid. Fifteen samples from nine recent
transplant recipients showed a mean TxB2 production of 583
65 (sEM) ngI3 x i08 platelets/5,' range 210 to 936 (P < 0.001).
Production at 0.5 and 0.75 mmoles AA was also increased.
Serum platelet agglutination titer. The majority of sera
showed normal platelet agglutination titers (0 or 0.5), but in 12
out of 42 samples the titer was 0.25 or greater. There was no
correlation between the degree of intraplatelet serotonin deple-
tion and the serum platelet agglutination titer.
Localization of platelet membrane antigen and PF4 in allo-
graft biopsy specimen. Biopsies were performed on 17 allograft
recipients within 90 days of allografting because of suspected
rejection or to assess graft prognosis. In ten, three injections of
intravenous methyl prednisolone had already been given in
addition to routine immunosuppression. None had thrombocy-
topenia (platelet count <150 X i09 platelets/liter) at the time of
biopsy, but all had very low intraplatelet serotonin concentra-
tions, undetectable in the majority. Nine of 17 biopsy specimen
showed positive results for platelet membrane antigen both
within glomeruli and in small blood vessels (Fig. 6). PF4 was
similarly distributed, but in a more diffuse, less granular pat-
tern. The degree of positivity roughly correlated with the
severity of rejection, the most intense being in two grafts, one
of which was already infarcted and the other failed within days
of the biopsy.
Discussion
In this study we have demonstrated prominent and prolonged
platelet activation in allograft recipients, in agreement with
previous data from platelet turnover studies in dogs [16] and
electron microscopy of human allograft biopsy specimen [1—3]
suggesting platelet localization and activation. Platelet activa-
tion appeared to be greatest during the first 3 months after
allografting, which agrees with the data of George et al on
platelet turnover in dogs [161. Surprisingly, however, there was
no evidence that platelet activation was greater in allografts
undergoing rejection which proved irreversible and those with
good function, albeit showing intermittent acute, reversible
rejection episodes.
This "background" platelet activation is so great (even in
allografts with good" function) during the first 3 months after
grafting that no further depletion was observed in the majority
of acute rejection episodes, although it may be seen on occasion
(Fig. 3). The slow return of intraplatelet serotonin toward
normal after 3 months presumably indicates some decrease in
stimuli which deplete intraplatelet amines. Others [28] have
observed depleted serotonin and ADP concentration in a few
allograft recipients, accompanied by ADP depletion.
We chose to measure PF4 concentrations rather than f3TG
concentrations, because /3TG is retained in the plasma in renal
dysfunction since the main route of removal is via the kidneys
[29]. In contrast, PF4 is taken up by endothelium [30] and
plasma levels are not affected by renal dysfunction. The plasma
PF4 levels were abnormal in a different pattern from the
serotonin concentrations (Fig. 4) — relatively normal for the
first few weeks and then persistently abnormal thereafter. In
the stable allografts both intraplatelet serotonin and plasma PF4
were abnormal. Differential secretion of platelet contents is well
recognized [31], but usually platelet amines require stronger
stimuli for release than those required to affect a-granule
secretion, at least in vitro.
The presence of amine-depleted platelets in the circulation
has been reported in a number of states of in vivo platelet
activation, including glomerulonephritis with circulating im-
mune complexes, and other immune complex diseases [21], and
dogs bearing dacron prostheses [321. This suggests that platelets
are returning to circulation after activation and release of
contents occurs somewhere within circulation or vasculature.
Such "hit and run" platelet activation is, of course, possible
within the allografted kidney, but under these circumstances
one would expect PF4 plasma concentrations to be elevated as
well.
In confirmation of data with labelled platelets [13—15] and
electron microscopy [1—3], we have shown by an immunofluo-
rescent technique that some platelets enter the kidney and are
trapped there; others may well return to the circulation, as
happens from intravascular prostheses [32], and in Mowbray's
observations of a transplanted kidney [13]. Platelet activation
could take place also in the circulation by platelet interaction
with circulating factors, such as immune complexes [33—35] or
the PAF-basophil system [36], but using the platelet-agglutina-
tion test we found only low titers of platelet agglutinating
material in our early allografts and no correlation with the
degree of serotonin depletion.
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Fig. 6. Cryostat section from an allograft biopsy specimen taken during a rejection episode, and stained with rabbit anti-human platelet membrane
antiserum, followed byfluorescein-conjugated swine anti-rabbit IgG. The glomerulus on the right (G), and the arteriole on the left (arrow) both
show strong fluorescence indicating the presence of platelet membrane antigens. Anti-PF4 antiserum gave similar results but in a more diffused and
less granular pattern.
One might anticipate that platelets from allograft recipients
might be less sensitive to aggregating agents in vitro, because of
the finding that circulating platelets were almost devoid of
serotonin and had released a-granule contents. A few patients
bearing transplants are among those previously described as
having an "acquired storage pool deficit" with intraplatelet
amine depletion and defective aggregation [281 but these were
thrombocytopenic. Observations were not made with arachi-
donic acid, and threshold aggregation concentrations were not
determined. Although our data using collagen were in general
agreement with this thesis, the ADP data were comparable with
normal, the threshold for arachidonic acid aggregation was
markedly reduced, and in vitro thromboxane generation was
increased markedly in autologous PRP. Thus, in patients with
allografts whose platelets have been stimulated to release
amines and a-granule contents, pathways dependent upon
thromboxane generation appear not only intact but are hyperac-
tive in vitro.
In agreement with these observations, Reimers et a! [37]
showed that rabbit platelets depleted of amines by in vitro
treatment with thrombin and then reinjected not only survived
normally but were hyperaggregable to ADP. Similar observa-
tions were made in dogs bearing prostheses (Dacron®) and with
circulating amine-depleted platelets [321 and in patients with
disseminated intravascular coagulation [38]. Further, Ingerman
et al [391 and Minkes, Joist, and Needleman [401 reported that in
inherited storage pool diseases of platelets (in which intraplate-
let amines are grossly reduced or absent) human platelets could
undergo normal aggregation with arachidonic acid in vitro.
Cazenave, Benveniste, and Mustard [41] reported also that
reacted and amine-depleted platelets could still respond to
PAF-acether. The continued circulation of such reacted, hyper-
aggregable platelets is of obvious importance, and we have
made similar observations in systemic lupus erythematosus
(Marchesi et a!, submitted for publication), rheumatoid arthri-
tis, and the hemolytic-uremic syndrome. The increased throm-
boxane production in vitro, if mirrored in vivo, may indicate
increased availability of platelet thromboxane precursors
through altered membrane lipids, in turn the result of reaction
with immune complexes or damaged endothelium. This possi-
bility is under study.
The possible effects of drugs taken by these patients on the
results must be considered. No patient was taking diazepam or
tranquillizer. Prednisone itself had no effect on either intraplate-
let serotonin or threshold aggregation to arachidonic acid
(Marchesi et al, submitted for publication); there are no data for
azathioprine but the cleared imidazolyl group would, if any-
thing, tend to reduce aggregability. Propanolol in large doses
inhibits platelet thromboxane production cx vivo [42], but our
patients were taking lower doses and there was no difference in
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our platelet serotonin concentrations, (as reported previously in
glomerulonephritis [211 or in aggregation threshold in those
patients on the drug and those not taking it; in any case, the
effect would be to inhibit arachidonic acid aggregation and (in
the doses used) to raise intraplatelet serotonin concentrations.
The same holds true of the minority taking hydrallazine.
Furosemide has been reported to inhibit platelet aggregation
[43] but at concentrations far above those achieved in clinical
use. Figure 3 indicates that even very large doses of methyl
prednisolone failed to inhibit the fall in intraplatelet serotonin
observed during acute rejection.
What is the clinical and theoretical significance of these
observations? Our hopes that simple measurement of indices of
platelet activation would either diagnose acute rejection in the
majority of patients, or predict graft outcome from early
observations have not been fulfilled. This does not deny a role
for platelets in allograft destruction, however. Any interaction
between damaged endothelium and platelets will lead to release
of inflammatory substances [441, platelet mitogens capable of
causing vascular proliferation [45, 46] which may relate to the
vascular occlusion found in rejecting allografts [47], and the
associated glomerular changes [1, 48]. We have observed
platelet antigens in such lesions (Fig. 5). Despite lack of effect
with current antiplatelet agents in preserving graft functions
[49—56], newer agents directed at inhibiting thromboxane syn-
thesis may prove more useful. Certainly, transplant recipients
can be added to the growing list of conditions in which the
circulating platelets are depleted of contents, and in many
patients hyperaggregable to arachidonic acid ex vivo.
Note added in proof
After this paper was prepared, another manuscript
(CAPITANJ0 A, MANNUCCI PM, PONTICELLI C, PARETI F:
Detection of circulating released platelets after renal transplan-
tation. Transplantation 33:298—301, 1982) has come to our
attention. These authors also found evidence of platelet activa-
tion in almost all of 46 transplant recipients. Their results differ
from ours, however, in that they found greater deviations from
normal in platelet serotonin and plasma f3-thrombo globulin in
patients with acute rejection and. chronic rejection when com-
pared with those having good functioning grafts.
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